


بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



Efficacy of the new Direct Acting Antiviral drugs in the treatment of Thalassemic HCV patients

Thesis

Submitted for partial fulfillment of the MD degree
in Internal Medicine

By

Sherif Ahmed Megahed Ahmed

M.B.B.Ch, M.SC

Faculty of Medicine-Ain Shams University

Under Supervision of

Prof. Dr. Maha Abd-Elaziz El Touny

Professor of Internal Medicine and Gastroenterology

Faculty of Medicine - Ain-Shams University

Prof. Dr. Ossama Ashraf Ahmed

Professor of Internal Medicine and Gastroenterology

Faculty of Medicine - Ain-Shams University

Prof. Dr. Iman Ahmed Ragab

Professor of Pediatrics

Faculty of Medicine - Ain-Shams University

Dr. Gina Gamal Naguib

Lecturer of Internal Medicine and Gastroenterology

Faculty of Medicine - Ain-Shams University

Dr. Shereen Abdel Monem Ibrahim

Lecturer of Clinical Pathology

Faculty of Medicine - Ain-Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٢٢



First, thanks are all due to **Allah**, for Blessing this work until it has reached its end, as a part of his generous help throughout our life.

My profound thanks and deep appreciation to **Prof. Dr. Maha Abd-Elaziz El Touny**, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain-Shams University, for her great support and advice, her valuable remarks that gave me the confidence and encouragement to fulfill this work.

I am deeply grateful to **Prof. Dr. Ossama Ashraf Ahmed**, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain-Shams University, for adding a lot to this work by his experience and for his keen supervision.

I am also thankful to **Prof. Dr. Iman Ahmed Ragab** Professor of pediatrics, Faculty of Medicine - Ain-Shams University, for her valuable supervision, co-operation and direction that extended throughout this work.

I would like to direct my special thanks to **Dr. Gina Gamal Naguib**, lecturer of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain-Shams University, for her invaluable help, fruitful advice, and continuous support offered to me and guidance step by step till this essay finished.

I cannot forget the great help of **Dr. Shereen Abdel Monem Ibrahim**, lecturer of clinical pathology, Faculty of Medicine - Ain-Shams University, for her invaluable efforts, tireless guidance and for her patience and support to get this work into light.

I am extremely sincere to **my family** who stood beside me throughout this work giving me their support.

Words fail to express my love, respect and appreciation to **my wife** for her unlimited help and support.



Sherif Ahmed Megahed

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	iii
List of Figures	v
Introduction	1
Aim of the Study	4
Review of Literature	
Hepatitis C Virus.....	5
Treatment of HCV Infection	27
Thalassemia	57
Chronic hepatitis C and Thalassemia.....	78
Subjects and Methods	91
Results.....	99
Discussion	123
Summary	131
Conclusion.....	134
Recommendations	135
References	136
Arabic Summary	—

List of Abbreviations

Abbr.	Full-term
A.A.	Amino acids
ALD	Alcoholic liver disease
Apo	Apolipoproteins
APRI	Aspartate aminotransferase to platelet ratio index
ART	Antiretroviral therapy
BMT	Bone marrow transplantation
BTM	β -thalassemia major
CHC	Chronic hepatitis C
CMV	Cytomegalovirus
DAAs	Direct acting antivirals
DDIs	Drug–drug interactions
DM	Diabetes mellitus
EASL	European Association for the Study of the Liver
EDHS	Egyptian Demographic Health Survey
EPO	Erythropoietin
eGFR	Estimated glomerular filtration rate
EHIS	Egyptian Health Issues Survey
EIA	Enzyme immunoassay
ESCRT	Endosomal-sorting complex required for transport
ER	Endoplasmic reticulum
ESRD	End stage renal disease
FIB4	Fibrosis 4
GIT	Gastrointestinal tract
HAV	Hepatitis A virus
HAMP	Hepcidin antimicrobial peptide
HB	Hemoglobin
HBV	Hepatitis B virus
HCC	Hepatocellular Carcinoma
HCV	Hepatitis C virus
HIV	Human Immunodeficiency Virus
HSC	hepatic stellate cells
HTN	Hypertension

IFN	Interferon
INR	International normalised ratio
LDs	Lipid droplets
LIM	Liver iron concentration
MASRI	Faculty of medicine Ain shams university research institute
MELD	Model End Stage Liver Disease
MRI	Magnetic resonance imaging
MSM	Men who have sex with men.
NAFLD	Non-alcoholic fatty liver disease
NAT	nucleic acid testing
NCCVH	National Committee for the Control of Viral Hepatitis.
NHL	Non Hodgkin lymphoma
NPIs	Nucleoside polymerase inhibitors
NS	Non Structural
NTDT	Non-transfusion dependent thalassaemias
NTPase	Nucleoside triphosphatase
NTPI	Non-transferrin-bound iron
OST	Opioid substitution therapy
PIs	Protease inhibitors
PWID	People who inject drugs
RBV	Ribavirin
RDTs	Rapid diagnostic tests
RNA	Ribonucleic acid
ROS	Reactive oxygen species
SVR	Sustained viral response
SQUID	Superconducting quantum interference device
TDT	Transfusion dependent thalassaemia
US	United states of America
WHO	World Health Organization

List of Tables

Table No.	Title	Page No.
Table (1):	The various iron chelation.....	71
Table (2):	ECOG performance status.....	95
Table (3):	Classification of study groups.....	100
Table (4):	Comparison between the four study groups regarding the Co-morbidities.....	100
Table (5):	Comparison between group (I) HCV Thalassemic patients subgroups regarding Iron chelating agents	101
Table (6):	Comparison between the four groups of the study regarding FIB 4 score before treatment.....	103
Table (7):	Comparison between the four groups of the study regarding FIB 4 score after treatment.....	104
Table (8):	Comparison between the four groups of the study with each other regarding Risk of Advanced Fibrosis (FIB4 Interpretation) before treatment	106
Table (9):	Comparison between the four groups of the study with each other regarding Risk of Advanced Fibrosis (FIB4 Interpretation) after treatment	107
Table (10):	Comparison between the FIB4 score of each group of the study before treatment and after treatment.....	109

Table (11): Comparison between the four groups of the study regarding HGB level before treatment.....	110
Table (12): Comparison between the four groups of the study regarding HGB level after treatment.....	111
Table (13): Comparison between the HGB Level of each group of the study before treatment and after treatment.....	113
Table (14): Comparison between group (I) HCV Thalassemic patients subgroups regarding Transfusion Assessment (units/month) at both start and end of treatment course	114
Table (15): Comparison between the four study groups regarding safety of the treatment (minor side effects).....	115
Table (16): Comparison between the four study groups regarding any major complication reported during treatment.....	116
Table (17): Comparison between the four study groups regarding Tolerability of the treatment.....	118
Table (18): Comparison between the four study groups regarding the Efficacy of the treatment (SVR12).	120
Table (19): Comparison between patients with positive HCV PCR (Non SVR) after treatment course regarding Quantitative HCV PCR.....	122

List of Figures

Figure No.	Title	Page No.
Figure (1):	HCV genome and proteins	8
Figure (2):	HCV entry and uncoating	13
Figure (3):	HCV replication and assembly	14
Figure (4):	Natural history of HCV infection.....	22
Figure (5):	Diagnosis of thalassemia.....	60
Figure (6):	Iron metabolism	66
Figure (7):	Schematic representation of mechanisms activating hepcidin transcription.....	69
Figure (8):	Effect of chelators	74
Figure (9):	Main causes of hepatic iron damage in thalassaemia.	82
Figure (10):	Comparison between the four study groups regarding the Co-morbidities.	101
Figure (11):	Comparison between group (I) HCV Thalassemic patients subgroups regarding Iron chelating agents	102
Figure (12):	Comparison between the four groups of the study regarding FIB 4 score before and after treatment.....	105
Figure (13):	Comparison between the four groups of the study with each other regarding Risk of Advanced Fibrosis (FIB4 Interpretation) before treatment	106

Figure (14):	Comparison between the four groups of the study with each other regarding Risk of Advanced Fibrosis (FIB4 Interpretation) after treatment	108
Figure (15):	Comparing the FIB4 score of each group of the study before treatment and after treatment.....	109
Figure (16):	Comparison between the four groups of the study regarding HGB level before and after treatment.	112
Figure (17):	Comparison between the HGB Level of each group of the study before treatment with its HGB Level after treatment.....	113
Figure (18):	Comparison between the four study groups regarding safety of the treatment (minor side effects)	116
Figure (19):	Comparison between the four study groups regarding any major complication reported during treatment.....	117
Figure (20):	Comparison between the four study groups regarding Tolerability of the treatment.....	119
Figure (21):	Comparison between the four study groups regarding the Efficacy of the treatment (SVR12)	121
Figure (22):	Comparison between patients with positive HCV PCR (Non SVR) after treatment course regarding Quantitative HCV PCR.....	122

Abstract

Background and Objectives: B-thalassemia major patients are susceptible to Hepatitis C Virus (HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient population is at risk of progression of liver fibrosis or development of cirrhosis as a consequence of both iron overload and HCV infection. However, patients with haemoglobinopathies and CHC have been excluded from the major clinical trials that led to the approval of DAAs. Hence, at present, limited experience is available regarding the safety and efficacy of DAAs in this population which is traditionally considered difficult to treat. Hence, this study was carried out to evaluate efficacy and safety of the combination regimen of sofosbuvir and daclatasvir for HCV infection in B-thalassemia major patients.

Methods: This study was conducted on 200 subjects divided into two groups, first group contains 150 HCV-Thalassemic patients while the second group contains 50 HCV only patients. Each group was classified into easy to treat or difficult to treat and received sofosbuvir 400mg + daclatasvir 60mg once/day for the duration of 12 or 24 weeks according to the NCCVH Hepatitis C treatment protocol 2015. Sustained virological response at post-treatment week-12 (SVR-12) was defined as negative HCV-RNA at week-12 post treatment.

Results: In group (I), successful SVR was achieved in all patients (100%) in subgroup (Ia) while in subgroup (Ib) 12 patients didn't achieve SVR (15.38%), 4 patients stopped due to side effects (5.13%) and 62 patients achieved SVR (79.49%) with overall successful SVR of 134 out of 150 HCV-Thalassemic patients in group (I) (89.33%). In group (II), 2 patients didn't achieve SVR (5.71%) and 33 patients achieved SVR (94.29%) in subgroup (IIa) while in subgroup (IIb) 2 patients didn't achieve SVR (13.33%) and 13 patients achieved SVR (86.67%) with overall successful SVR of 46 out of 50 HCV only patients in group (II) (92%). Few patients suffered from minor side effects that didn't require cessation of treatment but 4 patients developed major side effects in group (Ib) that required cessation of treatment. There were marked improvement in liver enzymes, Fib4 score, hemoglobin level and transfusion requirements in HCV-Thalassemic group after treatment.

Conclusion: A combination of sofosbuvir and daclatasvir is an efficacious and tolerable treatment regimen with negligible side effects for patients with thalassemia major and HCV infection.

Key words: Hepatitis C, Thalassemia, HCV Treatment, Sofosbuvir, Daclatasvir.

Introduction

Hepatitis C virus (HCV) infection is a public health problem worldwide and is a leading cause of cirrhosis and liver cancer (*Messina et al., 2015*). In Egypt, hepatitis C virus (HCV) infection has the highest prevalence rate in the world, which is estimated at 14.7% nationally (*Mohlman et al., 2015*). More than 90% of HCV infection in Egypt is due to genotype 4 which is the most common genotype in the Middle East and Africa (*Gower et al., 2014*).

Thalassemia is an autosomal recessive inherited blood disorder characterized by abnormal hemoglobin production due to genetic disorder leading defects in either the α or β globin chain, causing production of abnormal red blood cells that necessitate frequent blood transfusion and iron overload (*Weatherall, 2015*).

Hepatitis C virus infection has been reported in 4.4% to 85.4% of thalassemia patients that might be acquired through blood transfusion. The incidence of chronic hepatitis C was higher among thalassemia patients transfused before 1992, when screening of blood donors was still not available (*Nawfal, 2016*).

As chelation therapy with new drugs seems to prevent cardiac damage and improve survival, the chronic liver